Regenxbio Inc
Research Regenxbio Inc (RGNX) on Bullrun: market cap USD 482.60M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRGNX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 482.60M
- Financial periodQ2 2026
- RevenueUSD 108.02M
- Net incomeUSD 22.71M
- Free cash flow-USD 63.00M
- Gross margin99.0%
Valuation Snapshot
latest market cap is USD 482.60M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 170.44M | -USD 193.88M | -USD 126.38M | 88.1% | -3.76 | USD 34.47M | USD 73.50M | USD 102.73M |
| FY2024 | USD 83.33M | -USD 227.10M | -USD 175.56M | 59.7% | -4.59 | USD 57.53M | USD 82.03M | USD 259.65M |
| FY2023 | USD 90.24M | -USD 263.49M | -USD 228.37M | 58.8% | -6.02 | USD 34.52M | USD 89.29M | USD 311.74M |
| FY2022 | USD 112.72M | -USD 280.32M | -USD 238.21M | 51.6% | -6.5 | USD 96.95M | USD 88.50M | USD 516.20M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 482.60M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 732.84M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 383.02M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 789.66M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 981.90M | 14.5 | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.40B | 11.9 | n/a | n/a |
About Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Regenxbio Inc's market cap?
Regenxbio Inc's market capitalization is USD 482.60M.
What does Regenxbio Inc do?
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.